About Us

Molecular Targeting Technologies, Inc. (MTTI)

Our Mission: Translate novel radiopharmaceuticals for treatment and diagnosis of rare diseases.

Our Targets: supported by published data and ongoing Phase I clinical trials:


EBTATE (Lu-177-EB-DOTA-TATE), a neuroendocrine tumor therapy (NET). EBTATE shows several-fold increase of blood half-life and enhanced tumor uptake over existing peptide receptor radionuclide therapy (PRRT).

I-131-SapC-DOPS, a nanovesicle for glioblastoma multiforme (GBM), readily crosses the blood tumor/brain barrier delivering a dual killing effect to brain tumors.


TDURA (Tc-99m-duramycin), targets cell death in multiple applications including cardiotoxicity, atherosclerotic plaque, systemic inflammatory response syndrome (SIRS) and organ transplant rejection.

F-18-glucaric acid is being developed for detecting stroke and acute MI. Tc-99m-glucarate, was effective for MI detection in a phase II clinical trial.
*See pipeline page